TET2 and acute myeloid leukemia: TET2 gene alterations were anticipated to predict an increased response to hypomethylating agents and this predictive effect was explored in several cohorts of high-risk MDS, AML with low blast counts, and severe CMML patients [219,220,221,222,223].